Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ARVN

Arvinas

ARVN Rare disease Lead: Approved 8 Biotech Distilled articles ↓ 32 filings & releases ↓ Cash $88.0M (Sep 30, 2026) ↓ 8 verdicts ↓ 9 timing quotes ↓
NeurologyOncology Small Molecule

Market cap $420M 65.5M shares (10-Q, Oct 30, 2026) × $6.41 close Nov 6, 2026

Most recent annual filing: 2026-02-24

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. ARV-393 Ph1 interim2H 2026ARV-393 Ph1 interim, 2H 2026, notable
  2. ARV-806 KRAS readout4Q 2026ARV-806 KRAS readout, 4Q 2026, notable
  3. ARV-027 polyQ-AR readout1H 2027ARV-027 polyQ-AR readout, 1H 2027, notable
  4. ARV-102 Ph1 start2027ARV-102 Ph1 start, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Technology platforms

PROTAC Discovery Engine

Integrated suite of tools and expertise for discovery and optimization of PROTAC targeted protein degraders, including E3KnowledgeBase, ANGLE linker evolution, LEAP library format, PROTACify ML modeling, proteomics capabilities, and PIVOT PK/PD tool. Focus areas: oncology and neurology, including historically undruggable intracellular targets such as transcription factors, scaffolding proteins, and oncoproteins.

PROTAC

Proteolysis Targeting Chimera (PROTAC) protein degrader platform; harnesses the body's ubiquitin-proteasome system to degrade disease-causing proteins; applications in oncology (AR, ER, BCL6, HPK1) and neurology (LRRK2, polyQ-AR); enables oral delivery and blood-brain barrier penetration

Targets: AR, ESR1, BCL6, HPK1, LRRK2, polyQ-AR

PROTAC protein degrader platform

PROteolysis TArgeting Chimera (PROTAC) protein degrader platform that harnesses the body's natural protein disposal system to selectively and efficiently degrade disease-causing intracellular proteins, including historically undruggable targets; applied across oncology and neurology indications.

PROTAC · Pfizer

PROteolysis TArgeting Chimera protein degrader platform — harnesses the body's natural protein disposal system (ubiquitin-proteasome system) to selectively degrade disease-causing proteins; applied across oncology and neurology indications

Discontinued (1)

Capital (as filed)

Cash
$88.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$470M Sep 30, 2026
Operating cash flow
−$10.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$559M cash, runway 2H 2028 per the update of Nov 3, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Arvinas, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-04-10 Watch Arvinas (ARVN) - Scientific Deep Dive for Vepdegestrant, Luxdegalutamide, and Pipeline Products The PROTAC science is compelling but the commercial setup for vepdegestrant is muddy with no partner named, making it too risky to go long yet.
  2. 2026-05-02 Speculative buy speculative UPDATE: Arvinas (ARVN) - The First PROTAC Crosses the Finish Line FDA approval of the first-ever PROTAC eliminates modality risk and partially de-risks the platform, warranting a small speculative position while awaiting a commercial partner announcement.
  3. 2026-05-12 Buy core UPDATE: Arvinas (ARVN) - The Partner Lands. The Tape Yawns. Both major overhangs — FDA approval and commercial partner — are now resolved, and the pipeline is quietly delivering strong biomarker signals, justifying an upgrade to BUY despite Rigel being a mid-tier partner.
  4. 2026-06-02 Speculative buy speculative UPDATE: Arvinas (ARVN) - The KRAS Asset Gets the Novartis Treatment ARV-806 being punted to a future out-licensing partner narrows the wholly-owned pipeline thesis and concentrates bets on ARV-102 and ARV-393, warranting a downgrade to speculative.
  5. 2026-06-22 Watch UPDATE: Arvinas (ARVN) - The CMO Walks Three Weeks Before the Catalyst Window Opens A CMO departure three weeks before the catalyst window, stacked on top of a CEO transition and pipeline narrowing, raises execution risk enough to step back to the sidelines pending CMO succession and readouts.
  6. 2026-08-04 Speculative buy speculative UPDATE: Arvinas (ARVN) - The Catalyst Window Just Slid a Year Right The ARV-102 PSP clinical hold is procedural rather than a safety break, the balance sheet funds operations into 2H 2028 with no dilution gap, and the science thesis is intact — warranting a modest re-entry despite the one-year calendar slip.
  7. 2026-10-08 Speculative buy speculative UPDATE: Arvinas (ARVN) - ARV-102 Moves the Eyes, Not Yet the Needle ARV-102 produced a dose-dependent, placebo-controlled eye-movement signal in 24 PD patients, modestly lifting the scientific floor, but the PSP clinical hold remains unresolved so conviction does not scale.
  8. 2026-11-04 Watch UPDATE: Arvinas (ARVN) - The FDA Answered, and Arvinas Is Going Around It The U.S. PSP IND remains on hold after the tox package was submitted, ARV-806 has dropped off the pipeline deck, a second Big Pharma partner has exited, and a fresh $200M ATM prospectus at sub-cash prices raises dilution risk — warranting a return to the sidelines.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (9 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (32)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)